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Summary  A  17-month-old  vaccinated  Kuwaiti  boy  presented  with  meningitis.  The
Haemophilus  inﬂuenzae  type  b  (Hib)  capsular  antigen  was  detected  in  his  blood,
CSF  and  urine.  The  microorganism  failed  to  grow  in  culture.  This  case  represents
the  ﬁrst  report  of  possible  Hib  vaccine  failure  from  Kuwait.  This  report  examines
the  possible  reasons  for  this  failure  by  reviewing  the  literature  and  emphasizes  theinﬂuenzae  type  b
meningitis
need  to  broaden  the  deﬁnition  of  vaccine  failure  with  the  aim  of  optimizing  the
timing  of  the  vaccine  booster  dose  for  prematurely  born  children  and  establishing
continuous  surveillance  for  Hib  vaccine  failure.
©  2013  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.
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Haemophilus  inﬂuenzae  type  b  (Hib)  is a known
cause of  meningitis  and  other  invasive  diseases.  The
most common  presentation  of  invasive  Hib  disease
is meningitis,  which  is  frequently  accompanied  by
bacteremia.  This  presentation  accounts  for  approx-
imately  60%  of  all  cases  [1].  After  the  introduction
of the  Hib  vaccine,  the  Hib  infection  rate  declined
by 95—99%  [2,3].  In  2003,  a  booster  campaign  was
implemented  with  a  call-back  of  children  aged  6
months to  4 years  [4]. The  incidence  of  invasive
Hib disease  has  continued  to  decline  since  2004,
particularly after  the  introduction  of  the  12-month
booster in  2006,  which  followed  studies  showing
that protection  against  Hib  waned  during  the  sec-
ond year  of  life.  This  disease  is  currently  at  its
lowest  incidence  across  all  age  groups.  In  Kuwait,
the H.  inﬂuenzae  infection  rate  declined  from
1.27/100,000 population  in  1997  to  0.09/100,000
population in  2001  [5]. However,  it  remains  a public
health  problem  in  countries  where  Hib  vaccination
is not  routine.
The ﬁrst  case  of  Hib  vaccine  failure  from  Kuwait
is reported  here.  To  the  best  of  our  knowledge,  no
similar cases  have  been  reported  from  the  Middle
East region  to  date.  An  expansion  of  the  current
boundaries of  the  deﬁnition  of  vaccine  failure  is
suggested,  and  the  factors  that  may  contribute  to
vaccine failure  are  discussed.
Case report
A  17-month-old  Kuwaiti  boy  presented  to  the  Pedi-
atric Casualty  Department  on  September  1,  2005,
with a  2-day  history  of  a  cold,  difﬁculty  breathing
and refusal  to  eat  and  a  1-day  history  of  drowsiness.
He had  received  oral  ampicillin  for  2  days  prior  to
admission.
The child  was  the  product  of a non-
consanguineous  marriage,  born  by  preterm
cesarean section  at  27  weeks’  gestational  age
due to  maternal  preeclampsia.  He  was  kept  in  an
incubator  for  2  weeks  after  birth.On examination,  the  child  was  mildly  dehy-
drated, with  a  Glasgow  Coma  Scale  score  of
10/15 (EVM  scoring  —  opening  eyes  to  voice,  3;
responding to  painful  stimuli  by  withdrawing  the
f
e
[
(imb,  4;  persistently  irritable,  3).  His  temperature
as 35 ◦C,  which  peaked  at  38 ◦C on  the  same
ay. He  had  a heart  rate  of  165/min,  respiratory
ate of  66/min  and  blood  pressure  of  92/65  mmHg.
is pupils  were  small  and  reactive  to  light,  and
eningeal  signs  were  absent.  He  was  admitted  to
he Pediatric  Intensive  Care  Unit  (PICU).  Otitis  was
xcluded by  an  otolaryngologist  on  the  same  day.
A hemogram  showed  leukopenia  (WBC
530/mm3; 73%  neutrophils  and  13%  lympho-
ytes) and  thrombocytopenia  (34,500/mm3).
is serum  creatinine  was  115  mol/L  (normal
5—115 mol/L).  The  patient  had  disseminated
ntravascular  coagulation  (DIC),  with  a  prothrombin
ime of  26.1  s  (normal,  9.6—11.2  s),  an  activated
artial thromboplastin  time  of  57.6  s (normal,
7—33 s),  an  International  Normalized  Ratio  (INR)
f 2.51  and  a D-dimer  level  of  1000—2000  ng/mL
normal <250  ng/mL).  Therefore,  the  lumbar  punc-
ure was  deferred.  He  was  placed  on  mechanical
entilation and  intravenous  ﬂuids.  Empirically,
efotaxime 540  mg  IV  q6h,  teicoplanin  60  mg  IV
24h and  acyclovir  90  mg  IV  q8h  were  started.
one of  the  initial  or subsequent  cultures  (sent
wice weekly)  showed  any  growth.  Serology  for
denovirus, cytomegalovirus,  herpes  simplex  virus
nd varicella  zoster  was  negative.
The next  day,  his  fever  remained  (maximum
8.5 ◦C),  and  his  leukocyte  count  increased  to
3,500/mm3. The  child  developed  acute  renal  fail-
re. An  unenhanced  brain  CT  could  not  exclude
rain edema  or  cerebellar  hemorrhage.  The  neuro-
urgeon  deferred  any  surgical  intervention.  On  day
, ulcerative  ecchymoses  appeared  on  his  left  hand
nd right  leg.  Repeated  cultures  from  these  lesions
ere negative.
On day  4,  his  urine  was  tested  for  the  capsular
ntigens of  H.  inﬂuenzae  type  b,  Neisseria  menin-
itides  groups  A,  B,  C,  Y and  W135,  Streptococcus
neumoniae  and  Escherichia  coli  K12  using  a  latex
gglutination  test  (WELLCOGEN  BACTERIAL  ANTI-
EN KIT;  Remel  Europe  Ltd.,  UK;  sensitivity  96.7%,
peciﬁcity  99.5%,  positive  predictive  value  97.8%,
egative  predictive  value  99.7%).  It  was  positive  for
he Hib  antigen.  The  admission  blood  sample  was
ulture negative,  but  its  supernatant  was  positive
or the  Hib  antigen.  The  total  immunoglobulin  lev-
ls estimated  on  day  5  were  within  the  normal  range
IgG 8.96  g/L  (normal  4.9—13  g/L),  IgA  1.27  g/L
0.3—1.4  g/L)  and  IgM  1.0  g/L  (0.29—1.33  g/L)].
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Table  1  Results  of  the  speciﬁc  immunoglobulin-study.
Iga against  Patient-Ig  Minimum  level  Optimum  level
Hib  capsular  antigen  8  g/mL  0.15  g/mL  1  g/mL
Pneumococcal  polysaccharide  254  g/mL  10  g/mL  30  g/mL
Tetanus  toxoid  1.62  IU/mL  0.01  IU/mL  0.1  IU/mL
Diphtheria  toxoid  0.9  IU/mL  0.01  IU/mL  0.1  IU/mL
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Brain  magnetic  resonance  imaging  (MRI)  was
erformed with  multiplanar  sequences  pre-  and
ost-Gd  DTPA  and  showed  diffuse  leptomeningeal
nhancement  and  dural  enhancement  at  the  right
nterior  frontal  region.  There  was  widening  of  the
rontal subdural  space  that  was  greater  on  the  left
ide. The  remainder  of  the  brain  was  unremarkable.
hese ﬁndings  were  suggestive  of  meningitis  and
ubdural  effusion.
On day  10,  when  the  platelets  had  recov-
red (204,000/mm3),  a  lumbar  puncture  was
erformed. The  CSF-WBC  count  was  56/mm3 (43%
olymorphs  and  57%  lymphocytes),  and  the  CSF-
BC count  was  20/mm3.  No  microorganisms  were
bserved  using  a  direct  Gram’s  stain.  The  CSF
as further  analyzed,  with  the  following  results:
lucose, 3.5  mmol/L  (serum  glucose  5.7  mmol/L);
rotein, 1.12  g/L  (normal  0.15—0.45)  and  lactate,
.11 mmol/L  (1.1—2.8).  The  CSF  was  positive  for
he Hib  antigen  but  was  culture  negative.  Except
or a  mild  fever,  the  patient  was  stable,  and  he  was
xtubated  and  transferred  to  the  ward.
On day  11,  a  speciﬁc  serum  IgG  study  was  per-
ormed. The  results  are  shown  in  Table  1.
On day  13,  the  child  deteriorated.  He  developed
ever (38.2 ◦C),  drowsiness,  irritability,  deterio-
ated sensorium,  tachypnea,  muscle  hypotonia,
eck rigidity  and  convulsions.  His  peripheral  leuko-
yte count  was  21,400/mm3.  Brain  CT  showed
igns of  meningitis,  focal  brain  atrophy  and  hydro-
ephalus.  He  was  re-admitted  to  the  PICU  and
e-intubated. Rifampicin  110  mg  IV  q12h,  dexa-
ethasone  and  acetazolamide  were  added  to  the
reatment.  Six  days  later,  his  sensorium  improved,
nd he  was  extubated.
A  repeat  CSF  sample  sent  on  day  20  showed
eukocytes <1/mm3 and  erythrocytes  6/mm3. No
icroorganisms  were  observed  using  a  direct
ram’s stain.  The  CSF  tested  negative  for  bacterial
apsular polysaccharide  antigens,  including  that  of
ib. No  growth  was  observed  in  culture.
On  day  21,  the  child  was  transferred  to  the  wardith a  sporadic  fever.  Because  of  the  continuing
ever and  increasing  CSF  protein  level,  the  presence
f microabscesses  in  the  brain  and/or  antimicro-
ial resistance  of  the  microorganism  were  feared;
i
w
c
4efotaxime  was  continued  for  38  days  in  combina-
ion with  rifampicin,  which  was  administered  for  a
otal of 18  days.
By  day  41,  all  ulcerative  ecchymoses  had  dried
p, and  the  child  had  been  afebrile  for 5  consec-
tive days.  He  was  discharged  home  with  advice
o have  him  vaccinated  with  the  booster  dose  of
he Hib  vaccine  and  for  family  contacts  to  take
ifampicin prophylaxis.  He  was  also  referred  to  the
udiology  clinic.
After  3.5  years  of  follow-up,  the  child  was
ealthy and  without  any  clinical  neurological
equelae, although  no  formal  IQ  assessment  was
erformed.  The  patient  was  repeatedly  referred  to
he audiology  clinic  for  audiography  but  failed  to
isit.
iterature search
he  MEDLINE  database  was  searched  for  relevant
rticles published  from  1985  to  the  present.  We
earched  for  the  terms  ‘Haemophilus  inﬂuenzae
ype b’,  ‘vaccine  failure’,  ‘case  report’  and  ‘types
f Haemophilus  inﬂuenzae  type  b vaccines  in  use’.
dditional  papers  were  obtained  by  scanning  the
eference sections  of  the  articles  obtained  via  MED-
INE. Only  English-language  articles  were  included.
iscussion
n  Kuwait,  Hib  vaccination  has  been  a  part  of  the
ational  immunization  schedule  since  1998.  The
accine is  administered  at  the  ages  of  2,  4  and  6
onths, with  a booster  at  18  months.  The  vaccine
sed is  the  H.  inﬂuenzae  capsular  polysaccharide
oly-ribosyl-ribitol  phosphate  (PRP)  conjugated  to  a
etanus protein  and  combined  with  the  diphtheria-
etanus toxoid-whole  cell  pertussis  (DTwP)  vaccine
TETRACT-HIB,  supplied  by  Aventis-Pasteur).
Similar to  Kuwait,  in  the  USA,  the  Hib  vaccine
s administered  at  the  ages  of  2,  4  and  6  months,
ith a booster  at  15—18  months  [6]. The  Hib  vac-
ine in  the  Netherlands  was  given  at  the  ages  of  3,
, 5 and  11  months  from  April  1,  1993  to  December
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1998.  In January  1999,  the  schedule  changed  to  2,
3, 4  and  11  months  [7].  In  the  UK,  the  Hib  vaccine
was administered  at  2,  3 and  4 months  from  1992  to
2006, when  a  booster  at  12  months  was  introduced
[8].  The  vaccine  is  administered  at  2,  3  and  4
months of  age  in  the  Gambia,  without  a  booster  [9].
Over the  past  7 years,  this  patient  is  the  ﬁrst  case
of Hib  vaccine  failure  reported  from  Kuwait  and,  to
the best  of  our  knowledge,  from  the  entire  middle-
east region.  This  long  gap  without  any  reports  of
vaccine failure  could  either  be  due  to  the  excel-
lent immunogenic  potential  of  the  vaccine  in  use  or
to the  lack  of  a  nationwide  vaccine  failure  surveil-
lance  program.  The  patient  in  this  presented  case
had received  the  three  primary  doses  of  the  vaccine
and was  due  for  the  booster  dose  one  month  later.
Deﬁnition of vaccine failure
Vaccine  failure  is  deﬁned  as  invasive  Hib  disease
after completion  of  a  primary  vaccination  course  in
infancy. Heath  et  al.  [10]  deﬁned  invasive  disease
as the  isolation  of  H.  inﬂuenzae  from  a  normally
sterile site  or  a  positive  Hib  antigen  test  combined
with a  clinical  picture  compatible  with  invasive  H.
inﬂuenzae  disease.  The  Public  Health  Agency  of
Canada  [11]  deﬁnes  Hib  vaccine  failure  as  ‘‘The
onset  of  culture-conﬁrmed  invasive  (that  is,  involv-
ing a  normally  sterile  body-ﬂuid)  H.  inﬂuenzae  type
b infection  more  than  28  days  following  completion
of age-appropriate  immunization  for  the  speciﬁc  H.
inﬂuenzae type  b  vaccine  used.’’
UK surveillance  [12,13]  has  shown  that  antibody
concentrations wane  rapidly  after  primary  immu-
nization  in  infancy  and  that  a  booster  dose  in  the
second  year  of  life  is  necessary  to  provide  more
long-term protection  for  all  conjugate  vaccines,
suggesting that  countries  such  as  Kuwait  might  ben-
eﬁt from  earlier  timing  of  the  booster  dose,  such
as at  the  age  of  12  or  15  months  instead  of  18
months. A  national  surveillance  program  is  impor-
tant to  determine  how  early  the  booster  dose  of  the
Hib vaccine  can  be  given.
In the  present  case,  the  diagnosis  of  meningi-
tis was  supported  by  the  clinical  and  radiological
ﬁndings. This  case  fulﬁlls  the  deﬁnition  of  true
vaccine failure,  except  that  none  of  the  cultures
grew the  organism.  The  absence  of  growth  in  cul-
ture could  be  due  to  the  antibiotic  received  before
admission. Nevertheless,  the  detection  of  the  Hib
capsular antigen  in  three  normally  sterile  body  ﬂu-
ids (urine,  blood  and  CSF)  would  certainly  indicate
invasive  disease.
The neurological  deterioration  could  be  due  to
the subdural  effusion  rather  than  to  any  relapse  of
the infection  as  no  microorganisms  grew  in  any  of
B
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t
sP.  Purohit  et  al.
he  blood  and  CSF  cultures,  the  CSF  was  negative
or the  Hib  polysaccharide  antigen  and  the  patient
esponded  well  to  ﬂuid-lowering  agents  including
cetazolamide and  dexamethasone.
In agreement  with  Heath  and  McVernon  [14],  we
ropose  that  the  presence  of  a  speciﬁc  antigen  in
 normally  sterile  body  ﬂuid  supported  by  clinico-
adiological ﬁndings  should  be  added  to  the  present
eﬁnition  of  vaccine  failure.
actors associated with Hib vaccine failure
any  factors  can  be  associated  with  Hib  vac-
ine failure.  These  include  host-,  vaccine-  and
ommunity-related  factors.
ost-related  factors
ince  the  introduction  of  Hib  vaccination  in  the
K in  1992,  a history  of  premature  delivery  has
een found  to  be  the  most  frequent  clinical  con-
ition  associated  with  vaccine  failure  [10,14].  The
ate of  prematurity  among  UK  cases  is  similar  to
he national  background  rate  of  7.4%,  although  the
roportion  of  children  born  at  <34  weeks  (4%)  is
igher than  the  1.3%,  suggesting  that  the  extent
f prematurity  may  be  an  important  risk  factor
or vaccine  failure  [15]. In  premature  babies,  the
mmune system  may  not  be  mature  enough  to
ount a complete  immune  response  after  the  pri-
ary immunization,  and  this  incomplete  response
ay wane  earlier  than  expected  [13,14].
Our case  was  born  at  the  gestational  age  of  27
eeks, and  the  booster  was  due  1  month  after
e presented  with  the  disease.  Prematurity  and  an
arly waning  of  immunity  might  play  a  role  in  the
evelopment  of  invasive  disease.
Our patient  had  a high  Hib  capsular  antibody
iter (8  g/mL).  A  high  antibody  titer  on  day  11
n a previously  immunized  child  who  is  older  than
 year  of  age  is  more  likely  to  be  a  reﬂection  of
oosting by  infection  [16]. As  in  our  case,  McVer-
on et  al.  [16]  reported  that  after  Hib  meningitis,
accinated children  produce  higher  antibody  titers
han non-vaccinated  children,  showing  priming  for
mmunologic  memory  by  infant  immunization  with-
ut clinical  protection  from  the  disease.  In  the  late
990s, Booy  et  al.  [17]  suggested  that  a booster
ose of  Hib  vaccine  is  not  required  in  the  second
ear of  life  as  the  disease  was  on  the  verge  of  elim-
nation; however,  with  increasing  age,  they  noted
 small  decline  in  the  efﬁcacy  of  PRP-T  in  the  UK.
reukels  et  al.  [18]  inferred  that  inadequate  prim-
ng even  after  3—4  injections  of  the  Hib  vaccine  was
he reason  for  vaccine  failure  in  12  cases,  as  demon-
trated  by  normal  levels  of  total  Ig  but  reduced
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evels  of  anti-Hib  antibodies  and  reduced  avidity  of
ib-speciﬁc IgG2.
accine-related  factors
he vaccine  may  fail  if  it  has  lost  its  potency  due
o any  breach  in  the  cold  chain  during  transporta-
ion and  storage.  Because  there  were  no  similar
eported cases  in  Kuwait  during  that  time,  this  pos-
ibility is  unlikely.
Hib vaccine  failure  can  also  be  attributed  to
ther factors  such  as  changes  in  the  vaccination
chedule or  the  type  of  carrier  protein  used,  non-
peciﬁc  immunological  memory  to  the  conjugate
accine and  concomitantly  administered  vaccines.
hanges in  the  vaccination  schedule.  In the
etherlands, the  number  of  cases  of  Hib  disease
ncreased from  2  in  2000  to  15  in  2002  [19]. This
ncrease  was  hypothesized  to  be  due  to  changes  in
he Hib  vaccination  schedule  in  1999  [20].  There
ave  been  no  such  changes  in  the  Hib  vaccine  sched-
le in  Kuwait.
ype of  carrier  protein  used.  The  immunogenic-
ty of  the  Hib  PRP  is  increased  by  conjugating  it
o a  carrier  protein,  which  may  include  the  N.
eningitides  outer  membrane  protein  (PRP-OMP),
etanus protein  (PRP-T),  mutant  C.  diphtheriae
oxin protein  CRM  197  (HbOC)  or  diphtheria  toxoid
PRP-D).  Reports  on  the  immunogenicity  of  vaccines
t
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Table  2  Type  of  conjugate  in  use  in  some  countries.
Country  Type  of  co
United  Kingdom  [5,12,27]  PRP-Ta
HbOCb
PRP-T/DTwPc
PRP-T/DTaPd
The  Netherlands  [7]  PRP-T  
Gambia  [1,9]  PRP-T  
PRP-T  
Alaska  (Native  children  <5  years)  [30]  PRP-OMPe
HbOC/DTP  
PRP-OMP  and
B/PRP-OMP
Alaska  (non-native  children  <5  years)  [30] PRP-OMP  
HbOC/DTP  
PRP-OMP  and
B/PRP-OMP
a PRP-T: poly ribosyl ribitol phosphate conjugated to tetanus tox
b HBOC: Hib oligosaccharide conjugated with mutant diphtheria 
c PRP-T/DTwP: PRP-T combined with diphtheria-tetanus-whole c
d PRP-T/DTaP: PRP-T combined with diphtheria-tetanus-acellula
e PRP-OMP: PRP conjugated to N. meningitidis outer membrane  from  Kuwait  and  literature-review  103
ontaining  different  carrier  proteins  are  variable.
ranoff  et  al.  [21]  found  the  PRP-T  to  be  the  least
mmunogenic at the  age  of  1  year.  According  to  Latz
t al.  [22], immunogenicity  was  the  best  with  PRP-
MP. They  attributed  the  better  immunogenicity
f PRP-OMP  to  the  involvement  of  Toll-like  recep-
or 2  on  dendritic  cells.  Nevertheless,  the  Public
ealth Agency  of  Canada  [11]  has  reported  signiﬁ-
antly  higher  failure  rates  for  PRP-D  than  for  PRP-T.
owever,  PRP-T  was  not  followed  up  for  as  long
s PRP-D.  Batches  of  Hib  conjugate  vaccines  con-
aining PRP-D  were  withdrawn  in  the  USA  because
f questionable  immunogenicity  [23]. The  vaccine
sed in  Kuwait  is  a PRP-T.  The  different  types  of
onjugates  used  in  different  countries  are  shown
n Table  2, along  with  the  respective  failure  rates
uring  that  time  period.
on-speciﬁcity  of  immunological  memory.  As  in
ur case,  Anderson  et  al.  [24]  showed  that  children
ith  invasive  Hib  disease  in  both  vaccinated  and
nvaccinated  populations  had  antibody  responses,
hich  suggests  that  the  presence  of  immunological
emory was  not  sufﬁcient  to  protect  them  [25].
mmunological  memory  alone  may  not  be  sufﬁcient
o protect  against  invasive  disease  because  several
ays are  required  after  the  activation  of  immune
emory to  achieve  an  adequate  immune  response,
hich  is  too  long  to  effectively  protect  against  dis-
njugate  Period  of  use  Hib  disease  rate
1995—1996  108  cases
1994  59  cases
and  HbOC  1996—2000  0.63—1.8/100,000
persons
2000—2001  2.96/100,000
persons
1993—2000  1.85/100,000
persons
1997—2002  0/100,000  persons
2005—2006  3/100,000  persons
1992—1995  18.3/100,000
persons
1996—2000  47.6/100,000
persons
 Hepatitis 2001—2004  5.4/100,000  persons
1992—1995  3.5/100,000  persons
1996—2000  1.7/100,000  persons
 Hepatitis 2001—2004  0/100,000  persons
oid.
toxoid CRM197 (used during the catch-up campaign).
ell pertussis.
r pertussis.
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ease.  In  contrast,  the  presence  of  the  antibody  will
ensure the  rapid  and  effective  clearance  of  the
offending organism.
Effect  of  concomitantly  administered  vaccines.
Usonis and  Bakasenas  [26]  compared  the  immuno-
genicity  and  local  reactions  to  four  Hib  conjugate
vaccines (Hiberix,  ActHib,  Pedvax,  HibTITER)  when
administered  concomitantly  into  the  opposite
thigh with  a  diphtheria-tetanus-acellular  pertussis-
hepatitis  b-inactivated  poliovirus  vaccine.  The
immunologic  response  was  measured  in  terms  of
the anti-PRP  antibody  levels,  which  were  simi-
lar among  all  groups.  The  tetanus  conjugate  Hib
vaccine showed  the  fewest  local  reactions.  In  con-
trast, Kelly  et  al.  [27]  raised  some  doubts  regarding
the reliability  of  the  antibody  level  to  judge  the
immunogenic  potential  of  a  conjugate  Hib  vaccine
because  it  does  not  reﬂect  immunological  memory,
the avidity  and  isotype  of  the  antibodies  or  the
genetic make-up  of  the  population.  Our  case  was
observed  in  a  premature  infant,  but  his  total  and
speciﬁc  IgG  levels  were  normal.
Eskola et  al.  [28]  reported  that  the  use  of  an  Hib-
conjugated  vaccine  containing  acellular  pertussis
(DTaP-Hib)  instead  of  a  vaccine  containing  whole
cell pertussis  (DTwP-Hib)  was  associated  with  sig-
niﬁcantly  higher  Hib  vaccine  failure  rates.  However,
the vaccine  used  in  Kuwait  is  the  DTwP-Hib  contain-
ing PRP-T.
Community-related  factors
In the  community,  vaccine  failure  may  be  attributed
to continuous  exposure  to  the  organism  due  to  its
persistent  circulation  in  the  community  or  contin-
uous importation  from  other  communities.  In  the
UK, the  strains  responsible  for  cases  of  vaccine  fail-
ure have  been  reported  to  be  the  same  as  those
circulating in  the  pre-vaccine  era,  which  continue
to circulate  in  the  community  [29]. Donnelly  et  al.
[30]  and  McVernon  et  al.  [25]  suggested  that  circu-
lation of  the  microorganism  in  the  community  could
increase  the  occurrence  of  Hib  vaccine  failure.
In the  Gambia,  the  re-emergence  of  Hib  disease
was reported  during  the  years  2005—2006,  while
the same  vaccine  (PRP-T)  was  in  use.  The  impor-
tation of  the  organism  from  Senegal,  a  neighboring
country that  did  not  include  the  Hib  vaccine  in  its
national  program  at  that  time,  was  hypothesized
to have  played  a  role  in  the  re-emergence  of
Hib disease  in  the  Gambia  [9].  Kuwait  receives
large numbers  of  immigrants  from  South-East
Asia throughout  the  year.  Hib  vaccination  has  not
yet been  included  in  the  national  immunization
programs of  most  countries  in  that  region.  The
total Hib  vaccine  coverage  rate  is  only  24%  in  Africa
and Asia.  Bangladesh  is the  ﬁrst  South-East  AsianP.  Purohit  et  al.
ountry  to  introduce  the  Hib  vaccine  as  part  of  its
ational immunization  program  [31].
The vaccine  failure  rate  differs  around  the  globe,
s shown  in  Table  2.  Further  studies  are  required  to
xplore the  roles  of  racial  and  genetic  factors  in
accine failure.
The association  noted  between  invasive  infec-
ion and  social  deprivation  in  a study  by  McVernon
t al.  [32]  is  concerning  and  merits  further  investi-
ation.
onclusion
ur  case  describes  a true  Hib  conjugate  vaccine
ailure in  a  premature  child  who  developed  invasive
ib disease  prior  to  receiving  the  18-month  booster.
his case  report  calls  for  larger  population-based
tudies in  Kuwait  to  reassess  the  booster  timing  as
uch a decision  cannot  be  made  based  on  a  sin-
le case  report.  Such  studies  might  suggest  that
he booster  timing  in  Kuwait  should  be  earlier  to
rovide earlier  protection  or  that  premature  infants
ay need  a  separate,  more  intensive  schedule  that
rovides better  protection  over  a  longer  period  of
ime. These  results  could  be  extrapolated  to  other
olysaccharide  conjugate  vaccines  (e.g.,  the  pneu-
ococcal  and  meningococcal  vaccines).  As  the  ﬁrst
eported case  in  the  15  years  since  the  vaccine
as introduced  into  Kuwait’s  national  immuniza-
ion schedule,  this  report  highlights  the  need  for
he mandatory  reporting  of  such  cases  to  a  cen-
ral body.  Henceforth,  we  believe  that  establishing
nhanced population-based  surveillance  measures
s important  to  provide  the  data  necessary  to  make
uch decisions  in  Kuwait.
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